Exin Therapeutics

Exin Therapeutics is a Dutch biotechnology company dedicated to developing innovative cancer treatments by targeting the DNA damage response (DDR) mechanisms. Spun out from the Hubrecht Institute and UMC Utrecht, the company focuses on the Fanconi Anemia (FA) pathway, which is crucial for repairing DNA interstrand crosslinks. Exin's lead approach involves developing small molecule inhibitors that block this pathway, thereby sensitizing cancer cells to DNA-damaging chemotherapies and radiation. This strategy aims to overcome chemoresistance and improve the efficacy of existing standard-of-care treatments in various oncology indications. The company's research is grounded in the molecular mechanisms of DNA repair discovered in the laboratory of Professor Puck Knipscheer.